Three Investigator-Initiated Trials (IITs) to utilize the Elephas Live™ Platform to evaluate the impact of a combination therapy of surgical intervention and immunotherapy MADISON, Wis., Feb. 23, 2026 ...
MADISON, Wis., Jan. 8, 2026 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, ...
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of ...
A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors. Phase II basket study to evaluate the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Madison-based cancer ...
MADISON, Wis.--(BUSINESS WIRE)--#AACR--Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the acceptance of three ...
Premal H. Patel, MD, PhD, appointed Chief Medical Officer; Dr. Michael F. Giordano joins Scientific Advisory Board Cancer is a leading cause of death worldwide, with the number of patients projected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results